Fluorodeoxyglucose-positron emission tomography scan-positive recurrent papillary thyroid cancer and the prognosis and implications for surgical management

World Journal of Surgical Oncology

Volumn 10, Issue , 2012, Pages

  Schreinemakers, Jennifer M J ^a,b   Vriens, Menno R ^a,b   Munoz Perez, Nuria ^a,c   Guerrero, Marlon A ^a,d   Suh, Insoo ^a   Rinkes, Inne H M B ^b   Gosnell, Jessica ^a   Shen, Wen T ^a   Clark, Orlo H ^a   Duh, Quan Yang ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

^d UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; RADIOACTIVE IODINE; THYROGLOBULIN;

ADULT; ARTICLE; CANCER LOCALIZATION; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SIZE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; DEMOGRAPHY; DISEASE FREE SURVIVAL; DISEASE SEVERITY; FEMALE; HUMAN; MALE; OUTCOME ASSESSMENT; POSITRON EMISSION TOMOGRAPHY; PROSPECTIVE STUDY; THYROID PAPILLARY CARCINOMA;

ADULT; AGED; CARCINOMA; DISEASE-FREE SURVIVAL; FEMALE; FLUORODEOXYGLUCOSE F18; FOLLOW-UP STUDIES; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; POSITRON-EMISSION TOMOGRAPHY; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES; THYROID NEOPLASMS; TREATMENT OUTCOME;

EID: 84866173582     PISSN: None     EISSN: 14777819     Source Type: Journal    
DOI: 10.1186/1477-7819-10-192     Document Type: Article

References (16)

1. Hundahl SA, Fleming ID, Fremgen AM, Menck HR. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995. Cancer 1998, 83:2638-2648. 10.1002/(SICI)1097-0142(19981215)83:12<2638::AID-CNCR31>3.0.CO;2-1, 9874472.
2. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Sherman SI, Tuttle RM, American Thyroid Association Guidelines Taskforce Management guidelines of patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2006, 16:109-142. 10.1089/thy.2006.16.109, 16420177, American Thyroid Association Guidelines Taskforce.
3. Robbins RJ, Larson SM. The value of positron emission tomography (PET) in the management of patients with thyroid cancer. Best Pract Res Clin Endocrinol Metab 2008, 22:1047-1059. 10.1016/j.beem.2008.10.001, 19041831.
4. Rouxel A, Hejblum G, Bernier MO, Boelle PY, Menegaux F, Mansour G, Hoang C, Aurengo A, Leenhardt L. Prognostic factors associated with the survival of patients developing loco-regional recurrences of differentiated thyroid carcinomas. J Clin Endocrinol Metab 2004, 89:5362-5368. 10.1210/jc.2003-032004, 15531482.
5. Giammarile F, Hafdi Z, Bournaud C, Janier M, Houzard C, Desuzinges C, Itti R, Sassolas G, Borson-Chazot F. Is [18 F]-2-fluoro-2-deoxy-d-glucose (FDG) scintigraphy with non-dedicated positron emission tomography useful in the diagnostic management of suspected metastatic thyroid carcinoma in patients with no detectable radioiodine uptake?. Eur J Endocrinol 2003, 149:293-300. 10.1530/eje.0.1490293, 14514343.
6. Finkelstein SE, Grigsby PW, Siegel BA, Dehdashti F, Moley JF, Hall BL. Combined [18 F]Fluorodeoxyglucose positron emission tomography and computed tomography (FDG-PET/CT) for detection of recurrent, 131I-negative thyroid cancer. Ann Surg Oncol 2008, 15:286-292. 10.1245/s10434-007-9611-5, 17882493.
7. Frilling A, Tecklenborg K, Görges R, Weber F, Clausen M, Broelsch EC. Preoperative diagnostic value of [(18)F] fluorodeoxyglucose positron emission tomography in patients with radioiodine-negative recurrent well-differentiated thyroid carcinoma. Ann Surg 2001, 234:804-811. 10.1097/00000658-200112000-00012, 1422140, 11729387.
8. Zoller M, Kohlfuerst S, Igerc I, Kresnik E, Gallowitsch HJ, Gomez I, Lind P. Combined PET/CT in the follow-up of differentiated thyroid carcinoma: what is the impact of each modality?. Eur J Nucl Med Mol Imaging 2007, 34:487-495. 10.1007/s00259-006-0276-2, 17103166.
9. Nahas Z, Goldenberg D, Fakhry C, Ewertz M, Zeiger M, Ladenson PW, Wahl R, Tufano RP. The role of positron emission tomography/computed tomography in the management of recurrent papillary thyroid carcinoma. Laryngoscope 2005, 115:237-243. 10.1097/01.mlg.0000154725.00787.00, 15689742.
10. Rivera M, Ghossein RA, Schoder H, Gomez D, Larson SM, Tuttle RM. Histopathologic characterization of radioactive iodine-refractory fluorodeoxyglucose-positron emission tomography-positive thyroid carcinoma. Cancer 2008, 113:48-56. 10.1002/cncr.23515, 18484584.
11. Wang W, Larson SM, Fazzari M, Tickoo SK, Kolbert K, Sgouros G, Yeung H, Macapinlac H, Rosai J, Robbins RJ. Prognostic value of [18 F]fluorodeoxyglucose positron emission tomographic scanning in patients with thyroid cancer. J Clin Endocrinol Metab 2000, 85:1107-1113. 10.1210/jc.85.3.1107, 10720047.
12. Kim SJ, Lee TH, Kim IJ, Kim YK. Clinical implication of F-18 FDG PET/CT for differentiated thyroid cancer in patients with negative diagnostic iodine-123 scan and elevated thyroglobulin. Eur J Radiol 2009, 70:17-24. 10.1016/j.ejrad.2007.12.004, 18207685.
13. Grant CS, Thompson GB, Farley DR, Richards ML, Mullan BP, Hay ID. The value of positron emission tomography in the surgical management of recurrent papillary thyroid carcinoma. World J Surg 2008, 32:708-715. 10.1007/s00268-007-9361-3, 18204948.
14. Helal BO, Merlet P, Toubert ME, Franc B, Schvartz C, Gauthier-Koelesnikov H, Prigent A, Syrota A. Clinical impact of (18)F-FDG PET in thyroid carcinoma patients with elevated thyroglobulin levels and negative (131)I scanning results after therapy. J Nucl Med 2001, 42:1464-1469.
15. Wang W, Larson SM, Tuttle RM, Kalaigian H, Kolbert K, Sonenberg M, Robbins RJ. Resistance of [18f]-fluorodeoxyglucose-avid metastatic thyroid cancer lesions to treatment with high-dose radioactive iodine. Thyroid 2001, 11:1169-1175. 10.1089/10507250152741028, 12186505.
16. Mirallie E, Guillan T, Bridji B, Resche I, Rousseau C, Ansquer C, Bodet-Milin C, Curtet C, Carnaille B, Murat A, Charbonnel B, Kraeber-Bodere F. Therapeutic impact of 18FDG-PET/CT in the management of iodine-negative recurrence of differentiated thyroid carcinoma. Surgery 2007, 142:952-958. 10.1016/j.surg.2007.09.015, 18063081.